![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: GLYATL2 |
Gene summary for GLYATL2 |
![]() |
Gene information | Species | Human | Gene symbol | GLYATL2 | Gene ID | 219970 |
Gene name | glycine-N-acyltransferase like 2 | |
Gene Alias | BXMAS2-10 | |
Cytomap | 11q12.1 | |
Gene Type | protein-coding | GO ID | GO:0001676 | UniProtAcc | A0A024R4Z5 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
219970 | GLYATL2 | GSM4909285 | Human | Breast | IDC | 4.62e-04 | 1.81e-01 | 0.21 |
219970 | GLYATL2 | GSM4909290 | Human | Breast | IDC | 6.73e-13 | 5.44e-01 | 0.2096 |
219970 | GLYATL2 | GSM4909299 | Human | Breast | IDC | 2.04e-10 | 3.53e-01 | 0.035 |
219970 | GLYATL2 | GSM4909300 | Human | Breast | IDC | 1.03e-04 | 4.93e-01 | 0.0334 |
219970 | GLYATL2 | M2 | Human | Breast | IDC | 7.42e-04 | 6.29e-01 | 0.21 |
219970 | GLYATL2 | NCCBC6 | Human | Breast | DCIS | 6.29e-08 | 9.80e-01 | 0.2095 |
219970 | GLYATL2 | DCIS2 | Human | Breast | DCIS | 5.23e-33 | 4.88e-01 | 0.0085 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Breast | ![]() | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ | ||
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
GLYATL2 | SNV | Missense_Mutation | c.727T>C | p.Tyr243His | p.Y243H | Q8WU03 | protein_coding | tolerated(0.46) | benign(0.291) | TCGA-A2-A0D2-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
GLYATL2 | SNV | Missense_Mutation | novel | c.850N>G | p.His284Asp | p.H284D | Q8WU03 | protein_coding | deleterious(0.02) | probably_damaging(0.95) | TCGA-D8-A1Y1-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | PD |
GLYATL2 | SNV | Missense_Mutation | c.248N>G | p.Asp83Gly | p.D83G | Q8WU03 | protein_coding | tolerated(0.07) | benign(0.324) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
GLYATL2 | SNV | Missense_Mutation | c.241N>T | p.Ala81Ser | p.A81S | Q8WU03 | protein_coding | tolerated(0.15) | benign(0.041) | TCGA-A6-2680-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
GLYATL2 | SNV | Missense_Mutation | c.205G>A | p.Asp69Asn | p.D69N | Q8WU03 | protein_coding | deleterious(0.03) | probably_damaging(0.999) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
GLYATL2 | SNV | Missense_Mutation | c.590A>T | p.Gln197Leu | p.Q197L | Q8WU03 | protein_coding | deleterious(0.03) | probably_damaging(0.996) | TCGA-AA-A01K-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | folinic | CR | |
GLYATL2 | SNV | Missense_Mutation | c.426N>T | p.Lys142Asn | p.K142N | Q8WU03 | protein_coding | tolerated(0.53) | benign(0.014) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
GLYATL2 | SNV | Missense_Mutation | rs186979803 | c.173N>A | p.Arg58Gln | p.R58Q | Q8WU03 | protein_coding | tolerated(0.06) | probably_damaging(0.916) | TCGA-EI-6881-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5 | SD |
GLYATL2 | SNV | Missense_Mutation | novel | c.214N>G | p.Thr72Ala | p.T72A | Q8WU03 | protein_coding | deleterious(0.01) | possibly_damaging(0.868) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
GLYATL2 | SNV | Missense_Mutation | rs753668416 | c.741N>T | p.Lys247Asn | p.K247N | Q8WU03 | protein_coding | tolerated(0.07) | benign(0.187) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |